Adaptive Biotechnologies Corporation NASDAQ:ADPT

Founder-led company

Adaptive Biotechnologies stock price today

$12.38
+6.09
+96.82%
Financial Health
0
1
2
3
4
5
6
7
8
9

Adaptive Biotechnologies stock price monthly change

+57.25%
month

Adaptive Biotechnologies stock price quarterly change

+57.25%
quarter

Adaptive Biotechnologies stock price yearly change

+23.09%
year

Adaptive Biotechnologies key metrics

Market Cap
923.84M
Enterprise value
1.18B
P/E
-5.71
EV/Sales
6.40
EV/EBITDA
-6.80
Price/Sales
6.30
Price/Book
2.51
PEG ratio
-0.50
EPS
-1.49
Revenue
174.50M
EBITDA
-169.08M
Income
-215.05M
Revenue Q/Q
11.22%
Revenue Y/Y
-5.33%
Profit margin
-108.06%
Oper. margin
-108.03%
Gross margin
68.52%
EBIT margin
-108.03%
EBITDA margin
-96.89%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Adaptive Biotechnologies stock price history

Adaptive Biotechnologies stock forecast

Adaptive Biotechnologies financial statements

Adaptive Biotechnologies Corporation (NASDAQ:ADPT): Profit margin
Jun 2023 48.92M -47.81M -97.72%
Sep 2023 37.91M -50.3M -132.65%
Dec 2023 45.78M -69.44M -151.67%
Mar 2024 41.87M -47.50M -113.45%
Adaptive Biotechnologies Corporation (NASDAQ:ADPT): Analyst Estimates
Sep 2025 53.49M -41.76M -78.08%
Oct 2025 51.78M -39.81M -76.88%
Dec 2025 58.59M -35.26M -60.17%
Mar 2026 61.7M -50.71M -82.2%
  • Analysts Price target

  • Financials & Ratios estimates

Adaptive Biotechnologies Corporation (NASDAQ:ADPT): Debt to assets
Jun 2023 764540000 368.57M 48.21%
Sep 2023 717682000 356.04M 49.61%
Dec 2023 661134000 352.85M 53.37%
Mar 2024 620323000 345.55M 55.71%
Adaptive Biotechnologies Corporation (NASDAQ:ADPT): Cash Flow
Jun 2023 -23.55M 37.32M 1.46M
Sep 2023 -46.68M 26.13M 17K
Dec 2023 -26.93M 3.20M 87K
Mar 2024 -38.35M 44.50M 44K

Adaptive Biotechnologies alternative data

Adaptive Biotechnologies Corporation (NASDAQ:ADPT): Employee count
Sep 2023 790
Oct 2023 790
Nov 2023 790
Dec 2023 790
Jan 2024 790
Feb 2024 790
Mar 2024 709
Apr 2024 709
May 2024 709
Jun 2024 709
Jul 2024 709

Adaptive Biotechnologies other data

86.55% -7.43%
of ADPT is owned by hedge funds
123.21M -9.95M
shares is hold by hedge funds

Adaptive Biotechnologies Corporation (NASDAQ:ADPT): Insider trades (number of shares)
Period Buy Sel
Mar 2024 0 181388
Aug 2024 0 26922
Nov 2024 0 248
Transaction Date Insider Security Shares Price per share Total value Source
Sale
PISKEL KYLE officer: Chief Financial Officer
Common Stock 248 $4.98 $1,235
Option
BOBULSKY SUSAN officer: Chief Commercial Offic..
Common Stock 5,000 $1.98 $9,900
Option
BOBULSKY SUSAN officer: Chief Commercial Offic..
Stock Option (right to buy) 5,000 $1.98 $9,900
Sale
TAYLOR STACY L officer: SVP and General Counsel
Common Stock 26,922 $4.5 $121,068
Option
NEUPERT PETER M director
Common Stock 15,000 $0.84 $12,600
Option
NEUPERT PETER M director
Stock Option (right to buy) 15,000 $0.84 $12,600
Sale
PISKEL KYLE officer: Principal Accounting O..
Common Stock 7,727 $3.43 $26,504
Sale
TAYLOR STACY L officer: SVP and General Counsel
Common Stock 6,772 $3.43 $23,228
Sale
TAYLOR STACY L officer: SVP and General Counsel
Common Stock 6,609 $3.44 $22,735
Sale
LO FRANCIS officer: Chief People Officer
Common Stock 12,887 $3.43 $44,202
Patent
Application
Filling date: 20 Jan 2022 Issue date: 11 Aug 2022
Application
Filling date: 10 May 2021 Issue date: 28 Apr 2022
Grant
Filling date: 1 May 2020 Issue date: 15 Feb 2022
Application
Filling date: 9 Jun 2021 Issue date: 9 Dec 2021
Grant
Filling date: 11 May 2018 Issue date: 23 Nov 2021
Application
Filling date: 16 Apr 2021 Issue date: 7 Oct 2021
Grant
Filling date: 24 Nov 2015 Issue date: 20 Jul 2021
Grant
Filling date: 24 Feb 2016 Issue date: 29 Jun 2021
Grant
Filling date: 1 Apr 2016 Issue date: 22 Jun 2021
Grant
Filling date: 23 Dec 2016 Issue date: 8 Jun 2021
Insider Compensation
Mr. Chad M. Robins M.B.A, M.B.A. (1974) Co-Founder, Chief Executive Officer & Chairman
$1,120,000
Dr. Harlan S. Robins Ph.D. (1973) Co-Founder & Chief Scientific Officer $747,650
Ms. Julie Rubinstein (1972) Pres $734,770
Mr. Chad M. Cohen CPA (1975) Chief Financial Officer
$625,890
Dr. Mark Adams (1967) Chief Operating Officer & Chief Technology Officer
$403,400
Saturday, 7 December 2024
globenewswire.com
Tuesday, 3 December 2024
globenewswire.com
Friday, 29 November 2024
zacks.com
Tuesday, 26 November 2024
seekingalpha.com
Friday, 15 November 2024
zacks.com
Thursday, 7 November 2024
seekingalpha.com
zacks.com
zacks.com
globenewswire.com
Wednesday, 9 October 2024
globenewswire.com
Thursday, 29 August 2024
globenewswire.com
Thursday, 22 August 2024
globenewswire.com
Thursday, 1 August 2024
seekingalpha.com
zacks.com
zacks.com
globenewswire.com
Sunday, 21 July 2024
investorplace.com
Thursday, 11 July 2024
globenewswire.com
Friday, 31 May 2024
globenewswire.com
Wednesday, 29 May 2024
globenewswire.com
Thursday, 23 May 2024
investorplace.com
Wednesday, 22 May 2024
fool.com
Wednesday, 8 May 2024
The Motley Fool
Tuesday, 7 May 2024
Zacks Investment Research
Zacks Investment Research
Wednesday, 27 March 2024
InvestorPlace
Thursday, 22 February 2024
GlobeNewsWire
Wednesday, 14 February 2024
Seeking Alpha
Monday, 29 January 2024
GlobeNewsWire
Wednesday, 27 December 2023
GlobeNewsWire
  • What's the price of Adaptive Biotechnologies stock today?

    One share of Adaptive Biotechnologies stock can currently be purchased for approximately $12.38.

  • When is Adaptive Biotechnologies's next earnings date?

    Unfortunately, Adaptive Biotechnologies's (ADPT) next earnings date is currently unknown.

  • Does Adaptive Biotechnologies pay dividends?

    No, Adaptive Biotechnologies does not pay dividends.

  • How much money does Adaptive Biotechnologies make?

    Adaptive Biotechnologies has a market capitalization of 923.84M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 8.11% to 170.28M US dollars.

  • What is Adaptive Biotechnologies's stock symbol?

    Adaptive Biotechnologies Corporation is traded on the NASDAQ under the ticker symbol "ADPT".

  • What is Adaptive Biotechnologies's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Adaptive Biotechnologies?

    Shares of Adaptive Biotechnologies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Adaptive Biotechnologies's key executives?

    Adaptive Biotechnologies's management team includes the following people:

    • Mr. Chad M. Robins M.B.A, M.B.A. Co-Founder, Chief Executive Officer & Chairman(age: 51, pay: $1,120,000)
    • Dr. Harlan S. Robins Ph.D. Co-Founder & Chief Scientific Officer(age: 52, pay: $747,650)
    • Ms. Julie Rubinstein Pres(age: 53, pay: $734,770)
    • Mr. Chad M. Cohen CPA Chief Financial Officer(age: 50, pay: $625,890)
    • Dr. Mark Adams Chief Operating Officer & Chief Technology Officer(age: 58, pay: $403,400)
  • Is Adaptive Biotechnologies founder-led company?

    Yes, Adaptive Biotechnologies is a company led by its founders Mr. Chad M. Robins M.B.A, M.B.A. and Dr. Harlan S. Robins Ph.D..

  • How many employees does Adaptive Biotechnologies have?

    As Jul 2024, Adaptive Biotechnologies employs 709 workers.

  • When Adaptive Biotechnologies went public?

    Adaptive Biotechnologies Corporation is publicly traded company for more then 6 years since IPO on 27 Jun 2019.

  • What is Adaptive Biotechnologies's official website?

    The official website for Adaptive Biotechnologies is adaptivebiotech.com.

  • Where are Adaptive Biotechnologies's headquarters?

    Adaptive Biotechnologies is headquartered at 1165 Eastlake Avenue East, Seattle, WA.

  • How can i contact Adaptive Biotechnologies?

    Adaptive Biotechnologies's mailing address is 1165 Eastlake Avenue East, Seattle, WA and company can be reached via phone at +20 66 590067.

Adaptive Biotechnologies company profile:

Adaptive Biotechnologies Corporation

adaptivebiotech.com
Exchange:

NASDAQ

Full time employees:

709

Industry:

Biotechnology

Sector:

Healthcare

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

1165 Eastlake Avenue East
Seattle, WA 98109

CIK: 0001478320
ISIN: US00650F1093
CUSIP: 00650F109